Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dengue Fever
Researchers' work from University of Pennsylvania focuses on dengue fever
December 10th, 2008
"Dengue virus (DENV) infection is an expanding global threat to public health. Effective vaccine and treatment approaches remain elusive," scientists in the United States report. "B cell-directed vaccines may be complicated by an antibody-dependent enhancement (AIDE) phenomenon based on cross-serotype, nonneutralizing antibodies. We hypothesized that a CD8(+) T cell-directed genetic vaccine that targets a DENV nonstructural protein, NS1, could be a potential strategy to overcome the ADE barrier and accomplish cross-serotype protection. We selected an adenovirus-based vector as the dengue Vaccine carrier. To bypass preexisting immunity to human adenoviruses and to...
Source: Vaccine Weekly (2008-12-10)
|
